Short answer
FENNEC PHARMACEUTICALS INC. (FENC) filed an 8-K current report with the SEC on March 16, 2026 reporting Item 8.01 (Other Events). Settlement with Cipla grants PEDMARK® exclusivity protection through September 1, 2033, blocking generic sodium thiosulfate entry.
FENNEC PHARMACEUTICALS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Settlement with Cipla grants PEDMARK® exclusivity protection through September 1, 2033, blocking generic sodium thiosulfate entry
- License Agreement resolves patent litigation (D.N.J. Case No. 2:23-cv-00123); no damages or royalties mentioned, each party bears own costs
- "Earlier entry under specified circumstances" clause introduces conditional risk to the 2033 exclusivity date: terms not disclosed
- PEDMARK® is Fennec's sole commercial product; extended generic-free runway materially protects revenue through 2033
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other FENNEC PHARMACEUTICALS INC. 8-K filings
Get the next FENC 8-K as it lands
Follow FENC for push alerts, or ask the research agent what this filing means.